Supernus Pharmaceuticals, Inc. (LON:0LB2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.87B -4.6% |
| Revenue (ttm) | 625.90M +24.9% |
| Net Income | -82.82M |
| EPS | -1.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 12.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Open | 42.90 |
| Previous Close | 43.12 |
| Day's Range | 42.90 - 42.90 |
| 52-Week Range | 40.86 - 59.74 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizu... [Read more]
News
Supernus Pharmaceuticals Proxy statement: Proxy filing
Supernus Pharmaceuticals filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
Supernus Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is leveraging R&D and M&A to drive growth, maintaining strong revenue despite LOEs. Qelbree leads the ADHD franchise with rapid growth and significant market potential, while ONAPGO and ZURZUVAE expand the portfolio in movement disorders and women's health. Pipeline innovation focuses on novel CNS therapies.
Supernus Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted strong growth in CNS therapeutics, with Qelbree and ONAPGO outperforming expectations and Zurzuvae gaining momentum in postpartum depression. The pending Indivior merger is set to accelerate diversification and R&D, while the pipeline advances novel treatments for depression and epilepsy.
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-def...
Supernus Pharmaceuticals Earnings Call Transcript: Q2 2026
A merger of equals will create a CNS biopharma leader with $2.2B in pro forma revenue, five key growth products, and $125M in annual cost synergies. SUBLOCADE will be the largest revenue driver, and the combined company will have strong financial flexibility for future growth.
Supernus Pharmaceuticals Earnings release: Q2 2026
Supernus Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Supernus Pharmaceuticals Quarterly report: Q2 2026
Supernus Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Supernus Pharmaceuticals Slides: Q2 2026
Supernus Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Supernus Pharmaceuticals Proxy statement: Proxy filing
Supernus Pharmaceuticals filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Supernus Pharmaceuticals Proxy statement: Proxy filing
Supernus Pharmaceuticals filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Supernus Pharmaceuticals Proxy statement: Proxy filing
Supernus Pharmaceuticals filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of m...
Supernus and Indivior announce merger
Supernus Pharmaceuticals (SUPN) and Indivior (INDV) Pharmaceuticals (Nasdaq: INDV) entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leadi...
Supernus Announces Second Quarter 2026 Financial Results
ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have enter...
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus price target raised to $67 from $63 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Supernus (SUPN) to $67 from $63 and keeps an Overweight rating on the shares.
Supernus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is experiencing strong growth across its CNS-focused portfolio, with Qelbree, ZURZUVAE, and Onapgo driving expansion and significant peak sales potential. Business development remains a priority, supported by a robust balance sheet, while ongoing market education and supply chain enhancements are expected to further accelerate growth.
Supernus Pharmaceuticals to Participate in June Investor Conferences
ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
March saw a strong rebound in prescriptions after supply constraints, with robust ongoing demand and 970 patient forms in process. Supply capacity is secure through 2027, with additional suppliers planned. Qelbree continues double-digit growth, especially in adults, with significant market potential.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...
Supernus Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong revenue growth, driven by ONAPGO's rebound, robust Qelbree and ZURZUVAE performance, and improved operating results. Guidance for 2026 was reiterated, with a solid cash position and no debt supporting future growth.
Supernus Pharmaceuticals Earnings release: Q1 2026
Supernus Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.